Navigation Links
MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
Date:6/23/2011

EX (MAP0004, Orally Inhaled DHE) in Healthy Volunteers — Results from 3 Clinical Studies: Pooled analyses assessing the clinical pharmacokinetics of LEVADEX and its primary metabolite across three recent clinical studies show consistent pharmacokinetic results and rapid absorption via the pulmonary route of administration.

Abstract #: A-345-0001-00616

Poster presentations will be available on the Publications section of MAP Pharmaceuticals' website at http://www.mappharma.com by the conclusion of the Congress.

About LEVADEX® LEVADEX is an investigational drug for migraine. The Company has submitted a New Drug Application to the U.S. Food and Drug Administration for the potential acute treatment of migraine in adults. In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX had statistically significant improvement at two hours compared to patients on placebo for all four co-primary endpoints:

  • Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (p<0.0001);
  • Phonophobia free: 52.9 percent of patients who received LEVADEX compared with 33.8 percent for placebo (p<0.0001);
  • Photophobia free: 46.6 percent of patients who received LEVADEX compared with 27.2 percent for placebo (p<0.0001); and
  • Nausea free: 67.1 percent of patients who received LEVADEX compared with 58.7 percent for placebo (p=0.02).

  • The most common adverse event reported was medication aftertaste at six percent versus two percent for placebo.  The next most commo
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
    (Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
    (Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
    Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
    ... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
    ... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
    Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
    (Date:6/29/2015)... ... June 29, 2015 , ... New research ... fewer than 10 percent of U.S. state and local governments have implemented Next ... implementation deadline for NG9-1-1. , “Mobile phones have surpassed land lines as ...
    (Date:6/29/2015)... ... 2015 , ... The Food Safety and Technology Research Centre ... Polytechnic University (PolyU) has developed a new method for rapid authentication of edible ... long-term issue in food safety, and becomes particularly important with the emergence and ...
    (Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of the ... of the double chin and redefining of the jawline. Excess fat under the ... and heavier causing the person distress and poor self-image. , Kybella was produced by ...
    (Date:6/29/2015)... ... 29, 2015 , ... DISC, a method of behavioral analysis ... for corporate training seminars. As many as seventy percent of Fortune 500 companies ... increase productivity. , With the demand for in-house DISC training continuing to ...
    (Date:6/29/2015)... , ... June 29, 2015 , ... Care to Care, ... to Care. , Dr. Faber will lead the Radiation Oncology Services Program, with a ... the use of Care to Care’s proprietary evidence based criteria. He will assist ...
    Breaking Medicine News(10 mins):Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2Health News:As Demand for DISC Trainers Rises, PeopleKeys Offers Support with “THE DISC FACTOR—Train the Trainer” Webinar 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 3
    ... can be risky, research suggests , , THURSDAY, April 3 (HeathDay News) ... time to have your first child? , Turns out, that,s just ... next baby -- if you decide to have more than one. ... risk of having a baby born premature and with a host ...
    ... G. Rendell today signed House Bill 874 into law., ... is designed to educate,pregnant women about the potential benefits ... the donation and storage of,umbilical cord blood when they ... committed to creating a first-rate public,education system, protecting our ...
    ... PITTSBURGH, April 3, 2008 , WHO: GNC, along with figure professionals ... WHAT: The MORE Magazine Health and Wellness Expo ... 12 -7 p.m. April 4, and 11 a.m. to 5 p.m. April 5, 2008 ... Avenues), Come to GNC,s ...
    ... March of Dimes,Fund-raising Walk Still All About Babies, WHITE ... call it, March of Dimes premier fundraising walk is all,about ... weekend in April in hundreds,of communities nationwide., This year, ... work to help moms and babies -- those born healthy ...
    ... place again in the,Texas Medical Center as Houston-based LifeGift ... and one of a handful in the nation --,with ... work,in that facility is expected to help save the ... "This building will provide us to the opportunity ...
    ... 3 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. (NASDAQ: NCST ; ... down as Vice President Finance & Administration and Chief ... company in a field,unrelated to any of NUCRYST,s businesses, ... for Mr. Lurier,s successor., "On behalf of the ...
    Cached Medicine News:Health News:When It Comes to Pregnancy, Timing Is Everything 2Health News:When It Comes to Pregnancy, Timing Is Everything 3Health News:GNC to Run Sweepstakes, Raffle Fitness Equipment at MORE Magazine Health and Wellness Expo 2Health News:March For Babies Has Celebrity Support -- Now It Needs Yours 2Health News:Houston-Based LifeGift Becomes State's Only Stand-Alone Organ and Tissue Recovery Agency 2Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: